Next-Generation Cancer Test Offered by Setolabo
At Setolabo, we are conducting clinical research at Kagawa University Hospital with the aim of socially implementing a new cancer test that can ultra-early detect 16 types of cancer simultaneously from a single blood draw.
In Japan, one in two people will develop cancer, and one in four will die from it.
However, if detected early, many cancers are treatable.
Nevertheless, the rate of cancer screening remains low—below 50%.
According to a Ministry of Health, Labour and Welfare survey, as of 2022 the participation rates for the five major cancer screenings (stomach, lung, colorectal, breast, and cervical) all remain in the 40–50% range, falling short of the 60% target.
“Don’t wait until it’s too late. Setolabo offers a new, easily accessible form of screening for everyone.
Innovative Cancer Screening Powered by miRNA
MiRNA (microRNA) in the blood changes even at the very earliest stages of cancer. Setolabo is developing an AI-driven test that ultra-early detects 16 types of cancer—including breast, lung, and colorectal—from a single drop of blood. We’re collaborating with Kagawa University School of Medicine and other institutions worldwide on clinical research, with the goal of rolling out this test globally.
Making Cancer Screening a Routine, Not a Rare Event
Work, childcare, busy days—but protecting your health shouldn’t be hard. We’re transforming cancer screening from something you only do “after you feel unwell” into something you undergo “regularly while you’re healthy.” In doing so, we aim to help build a society that saves as many lives as possible.